Medication info
Allestek Plus Tablet 20/12.5 mg

Allestek Plus Tablet 20/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
FarmGen Science Co., Ltd.
Appearance
Yellowish-red round film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201100888 · Approved 2011.02.24 · Insurance code 670103220

Summary

Main use
Treatment of essential hypertension when blood pressure is not adequately controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Before administering this medicine, it is recommended that the dose of olmesartan medoxomil or hydrochlorothiazide be adjusted separately. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this medicine once daily, regardless of meals. Adjust the dose at intervals of 2~4 weeks, taking the patient's blood pressure response into consideration. A marked reduction in blood pressure may occur when olmesartan medoxomil is coadministered or when switching to this medicine (olmesartan medoxomil/hydrochlorothiazide) in patients taking high doses of hydrochlorothiazide alone and in patients with volume depletion or hyponatremia. In such cases, reduce the dose of hydrochlorothiazide to 12.5mg before coadministering olmesartan medoxomil. <Older adults> In older adults, start with the lowest dose and use caution when adjusting the dose, taking the patient's renal or cardiac function, comorbidities, and other concomitant medications into consideration. <Patients with renal failure> This medicine (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal failure (creatinine clearance>30mL/min). Do not administer this medicine (olmesartan medoxomil/hydrochlorothiazide) to patients with more severe renal failure, as loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic failure> Use of this medicine is not recommended because there is no experience with its use in patients with hepatic failure.
Child dose
<Children> The safety ⦁ efficacy in children have not been established.

Ingredients

Manufacturer
FarmGen Science Co., Ltd.

Efficacy & effects

Treatment of essential hypertension when blood pressure is not adequately controlled with monotherapy

  • Essential hypertension
View approved original text

Olmesartan medoxomil and hydrochlorothiazide are medications used to treat essential hypertension. When blood pressure control is difficult with monotherapy, this combination helps effectively lower blood pressure. This medication contributes to maintaining blood pressure within the normal range by promoting blood vessel dilation and excessive salt excretion. This helps prevent complications such as heart disease and stroke. It plays an important role in establishing an appropriate treatment plan tailored to the patient's blood pressure status. Therefore, it is safely and effectively used in the treatment of essential hypertension.

How to take

Adult dose

Before administering this medicine, it is recommended that the dose of olmesartan medoxomil or hydrochlorothiazide be adjusted separately. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this medicine once daily, regardless of meals. Adjust the dose at intervals of 2~4 weeks, taking the patient's blood pressure response into consideration. A marked reduction in blood pressure may occur when olmesartan medoxomil is coadministered or when switching to this medicine (olmesartan medoxomil/hydrochlorothiazide) in patients taking high doses of hydrochlorothiazide alone and in patients with volume depletion or hyponatremia. In such cases, reduce the dose of hydrochlorothiazide to 12.5mg before coadministering olmesartan medoxomil. <Older adults> In older adults, start with the lowest dose and use caution when adjusting the dose, taking the patient's renal or cardiac function, comorbidities, and other concomitant medications into consideration. <Patients with renal failure> This medicine (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal failure (creatinine clearance>30mL/min). Do not administer this medicine (olmesartan medoxomil/hydrochlorothiazide) to patients with more severe renal failure, as loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic failure> Use of this medicine is not recommended because there is no experience with its use in patients with hepatic failure.

Child dose

<Children> The safety ⦁ efficacy in children have not been established.

Precautions

This medication can cause severe harm or even death to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately if pregnancy is confirmed. Patients with allergies to the ingredients of this medication or certain kidney and liver function disorders should not take it. Patients with reduced blood volume or certain heart, kidney, or liver diseases should use this medication with caution and monitor for symptoms of low blood pressure closely at the start of treatment. This medication can affect electrolyte balance in the body, so regular blood tests should be conducted to check levels of sodium, potassium, and other electrolytes. Dizziness or symptoms of low blood pressure may occur during treatment, so caution is advised when engaging in hazardous activities such as operating machinery or driving. This medication can cause photosensitivity, increasing the risk of skin cancer, so sun exposure should be avoided and skin conditions should be regularly checked. There is a possibility of drug interactions while taking this medication, especially with potassium supplements, diuretics, lithium, and non-steroidal anti-inflammatory drugs, so it is important to consult with a doctor or pharmacist when used concurrently. Breastfeeding women may experience adverse reactions in their infants while taking this medication, so it is recommended to either stop breastfeeding or discontinue the medication. The safety and efficacy for pediatric use have not yet been established, so caution should be exercised when administering to children. Elderly patients may have reduced kidney and liver function, so treatment should start at a low dose and be monitored closely. In cases of overdose, symptoms such as low blood pressure, electrolyte imbalance, and dehydration may occur, necessitating immediate medical attention.

Side effects

  • nausea
  • hyperuricemia
  • dizziness
  • upper respiratory infection
  • headache
  • urinary tract infection
  • chest pain
  • back pain
  • peripheral edema
  • vertigo
Show 75 more
  • abdominal pain
  • dyspepsia
  • gastroenteritis
  • diarrhea
  • elevated AST
  • elevated GGT
  • elevated ALT
  • hyperlipidemia
  • elevated creatine phosphokinase
  • hyperglycemia
  • arthritis
  • arthralgia
  • myalgia
  • cough
  • rash
  • hematuria
  • facial edema
  • weakness
  • angioedema
  • anaphylactic reaction
  • vomiting
  • hair loss
  • pruritus
  • urticaria
  • rhabdomyolysis
  • acute kidney failure
  • increased serum creatinine
  • palpitations
  • hypercholesterolemia
  • hypertriglyceridemia
  • flu-like symptoms
  • pharyngitis
  • rhinitis
  • sinusitis
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • jaundice
  • hepatitis
  • acute cholecystitis
  • necrotizing vasculitis
  • interstitial pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • orthostatic hypotension
  • arrhythmia
  • transient blurred vision
  • jaundice
  • choroidal exudate
  • frailty
  • Stevens-Johnson syndrome
  • erythema multiforme
  • exfoliative dermatitis
  • toxic epidermal necrolysis
  • loss of appetite
  • thirst
  • abdominal discomfort
  • constipation
  • abdominal colic
  • pancreatitis
  • sialadenitis
  • dry mouth
  • fatigue
  • drowsiness
  • emotional blunting
  • restlessness
  • thrombocytopenia
  • leukopenia
  • aplastic anemia
  • hemolytic anemia
  • purpura
  • elevated blood pressure
  • nasal bleeding
  • asthma
  • elevated serum creatinine
  • elevated blood pressure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. The appropriate storage temperature is room temperature between 1 degree and 25 degrees Celsius. This will help maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Yellowish-red round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.